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Abstract 
 
Purpose: Using a retrospective analysis of treatment plans submitted from multiple institutions 
accruing patients to the RTOG #0236 non-small cell SBRT protocol, this study determines the dose 
prescription and critical structure constraints for future SBRT lung protocols that mandate density 
corrected dose calculations. 
Method and Materials: A subset of twenty patients from four institutions participating in the 
0236 protocol and using superposition/convolution algorithms are compared. The 0236 
protocol required a prescription dose of 60 Gy delivered in three fractions to cover 95% of the 
PTV volume.  Additional requirements were specified for target dose heterogeneity and dose 
to normal tissue/structures. The protocol required each site to plan the patient’s treatment 
using unit density, and another plan with the same monitor units and applying density 
corrections was also submitted. These plans have been compared to determine dose 
differences.  A two-sided paired student’s t-tests were used to evaluate these differences. 
 
Results: With heterogeneity corrections applied, the volume of PTV receiving 60 Gy or more 
(V60) decreased on average 10.1% (SE=2.7%) from 95% (p=0.001). Maximum dose to any 
point 2 cm or greater away from the PTV increased from 35.2 Gy (SE =1.7 Gy) to 38.5 
(SE=2.2 Gy).  
 
Conclusions: Statistically significant dose differences were found with heterogeneity 
corrections. The information provided in this study is currently being used for designing future 
heterogeneity corrected RTOG SBRT lung protocols to match the true dose delivered for 0236. 
 Key words: RTOG, Stereotactic Body, Radiation Therapy, Non-Small Cell Lung Cancer
 Purpose:  
Lung cancer remains the most frequent cause of cancer death in both men and women in 
North America. Lung cancer accounts for approximately 15% of all cancers diagnosed but 26-
31% of all cancer deaths. 1  These statistics have been more or less stable over the years 2-4 . 
Seventy-five percent of patients with bronchogenic carcinoma will be diagnosed with non-small 
cell lung cancer (NSCLC). Approximately 15-20% of NSCLC patients present with early or 
localized disease. 5  The number of patients diagnosed with stage I NSCLC is expected to rise 
significantly in the next several decades due to widespread screening with spiral CT scanning.6   
Surgical resection of stage I (T1-2, NO) NSCLC results in five-year survival rates of 
approximately 60-70%, 7-9  and remains the treatment of choice for this population. 
Unfortunately, some patients with early stage NSCLC are unable to tolerate the rigors of 
surgery or the post-operative recovery period due to lack of adequate respiratory reserve, 
cardiac dysfunction, diabetes mellitus, vascular disease, general frailty, or other co-morbidities. 
Primary radiotherapy for early stage non-small lung cancer is considered reasonable non-
surgical therapy for such patients, with reported five-year survival rates ranging from 10-30%. 
10-16  The standard approach involves giving approximately 45-66 Gy total dose in 1.8-2.0 Gy 
fractions. This regimen has been established based on early experience of treatment with 
radiation and has been justified by widely accepted models of radiobiological effects of x rays 
on human tissue. Early evaluations of radiation therapy showed that the delivery of large 
radiation field treatments was leading to unacceptably high toxicities17 . However, early 
radiotherapy delivery techniques were limited in the inability to decrease exposure of normal 
tissues due to low beam energies utilized. These treatments suffered also from large targeting 
uncertainties caused by the unavailability of modern imaging techniques and less than ideal 
representations of the dose distribution inside the patient anatomy18 . 
Newer techniques such as 3-D conformal radiotherapy (3D-CRT) have been proven to allow 
significant dose escalation of fractionated radiotherapy in locally advanced lung cancer in a 
Radiation Therapy Oncology Group (RTOG) trial. 19  SBRT, which utilizes elements of 3-DCRT 
in addition to stereotactic localization, incorporates a variety of systems for decreasing the 
effects of lung and other organ motion that would otherwise translate into target motion. These 
systems allow even more dramatic reduction of treatment volumes facilitating hypofractionation 
with markedly increased daily doses and significantly reduced overall treatment time. RTOG 
protocol 0236 is designed to determine if radiotherapy involving high biological dose with 
limited treatment volume (using SBRT techniques) achieves acceptable local control (i.e., ≥ 
80%) in frail patients with medically inoperable early stage non-small cell lung cancer.  
Dose calculation with/without tissue density corrections are reported to have dramatic 
deviations for radiotherapy planning especially in the thoracic region 20-23 . The differences 
exist for the dose to the isocentric point, and for the dose distributions, including target 
coverage and normal structure sparing. Many centers participating in RTOG trials for lung 
cancer did not have access to more accurate dose calculation techniques such as 
superposition/convolution algorithms or Monte Carlo method in 2000 and 2001 when RTOG 
0236 was being designed. In addition, phantom measurements and calculations reported in 
the literature showed that reasonable accuracy and more importantly consistency from center 
to center could be achieved by simply not using the vendor’s heterogeneity correction 
algorithm 24 . It was therefore decided not to allow tissue heterogeneity correction for 
calculating monitor unit settings for RTOG 0236 25 . As required by the protocol, all dose 
planning and calculation of monitor units for actual treatment were performed with all tissues 
assuming unit (water) density. However, in an effort to ultimately better understand these 
effects for improving future protocols, each plan was also calculated with software vendor 
supplied heterogeneity corrections and submitted for QA purposes. The computation using 
heterogeneity corrections had beam weights manipulated such that the number of monitor 
units was the same for each beam between the plans.  
This study evaluates those treatment plans with and without heterogeneity corrections 
submitted from multiple institutions accruing patients to RTOG protocol 0236 and reports on 
the effect of tissue density correction on the various dose objectives specified in the protocol. 
 
Method and Materials:  
This analysis was limited to those institutions which used treatment planning algorithms that 
approximate changes for lateral electron transport in contrast with those based on equivalent 
path length correction only. Studies have found that, if commissioned appropriately, models 
that consider changes in lateral electron transport tend to predict doses more accurately when 
compared with Monte Carlo calculations and/or actual dose measurements 26-30 . The planning 
systems and heterogeneity correction algorithms meeting these criteria were Pinnacle (Royal 
Philips Electronics of the Netherlands) collapsed cone  and CMS/XIO (The Elekta Group) 
superposition/convolution algorithms.  
The system from Pinnacle is based on a fluence model using collapsed cone convolution, in 
which the kernel is not separated into primary and scatter components during convolution 31-34 .  
The XiO system from CMS has two fluence dose calculation models, a Fast Fourier Transform 
(FFT) based convolution algorithm and a more exact multi-grid fast superposition method 35, 36  
. The FFT convolution is performed in the frequency domain with the kernel from Mackie et al 
37 
. For the multi-grid superposition method, during integration the kernels which are now 
represented in spherical coordinates are modified according to density changes in the 
irradiated medium with the use of a varying resolution for the calculation grid depending on 
potential dose gradients, e.g., at high density gradients and at beam edges a finer grid is used.  
A brief summary of the treatment planning requirements for the protocol 38  is given below.   
• Three-dimensional coplanar or non-coplanar beam arrangements will be custom designed 
for each case to deliver highly conformal prescription dose distributions.  Non-opposing, non-
coplanar beams are preferable.  Seven or more beams of radiation will be used with roughly 
equal weighting.  A typical beam arrangement is shown in Figure 1. 
• Field aperture size and shape should correspond nearly identically to the beam’s-eye view 
(BEV) projection of the PTV (i.e. no additional “margin” beyond the PTV) 
• All tissues within the body, including lung, were assumed to have unit (water) for planning 
calculation. However, each plan was also calculated, using the same monitor units as the unit 
density plan, with heterogeneity corrections enabled. The protocol required the submission of 
the corrected plan in digital form for QA purposes.  
• The plan should be normalized to a defined point corresponding closely to the center of 
mass of the PTV (called the COMPTV). 
• The prescribed dose of 60 Gy should cover 95% of the PTV.   
• A dose that is 90% of the prescribed dose (54 Gy) should cover at least 99% of the PTV. 
• Under the above conditions, the maximum dose within the target should fall between 67 
and 100 Gy. 
• Any dose greater than 105% of the prescription dose (63 Gy) should occur primarily within 
the PTV. The cumulative volume of all tissue outside of the PTV receiving a dose greater than 
105% of prescription dose (63 Gy) should be no more than 15% of the PTV.  
• Conformality of PTV coverage for this protocol is judged by the following constraints: 
o The ratio of the volume of the prescription isodose to the volume of the PTV is to be no 
more than 1.4 (Table 1). This criterion will not be required in treating very small tumors (< 2.5 
cm axial GTV dimension or < 1.5 cm cranio-caudal GTV dimension). 
o The falloff gradient beyond the PTV must be rapid in all directions and meet the following 
criterion: The maximum total dose in Gy to any point 2 cm or greater away from the PTV must 
be less than the number given in the column titled “maximum dose 2 cm from the PTV” in 
Table 1.  This table only lists unacceptable major deviations. 
o The ratio of the volume within the isodose surface corresponding to a dose of 50% of the 
prescription dose (30 Gy) to the volume of the PTV must be no greater than the R50% value 
given in Table 1.  
• The absolute maximum dose limits for critical structures are listed in Table 1 and Table 2.  
 
The protocol requires that the treatment planning data (including CTs, structures, 3D dose 
matrix, and plans) be exported from institution’s treatment planning systems and submitted to 
the Image Guided Therapy QA Center.  A Digital Data Integrity QA process was performed for 
each dataset, which included making sure all protocol required items were present and intact, 
that images, structures, and dose distributions were spatially registered, and that doses were 
properly scaled.  Structures were assigned protocol-specified names and DVHs were 
recalculated with consistent spatial sampling and dose bin width parameters for both 
heterogeneity-corrected and uncorrected dose matrices.  Dose-volume statistics were then 
computed from these DVHs.  
 
Statistical methods 
Since there is a relationship for each patient between the dosimetric data with and without 
heterogeneity corrections applied, changes in dosimetric data with heterogeneity corrections 
must be analyzed for each patient.  The difference between dosimetric data with and without 
heterogeneity corrections was calculated by subtracting the non-corrected dose from the dose 
using heterogeneity corrections.  A two-sided paired student’s t-test was then applied to that 
difference using the null hypothesis that the actual mean does not differ significantly from 0. 
 
Results and discussions:  
Fifty-nine patients were accrued to RTOG 023639 .  Of these, 20 patients from 4 institutions 
met the criteria set in the protocol for this analysis. The PTV volumes for the patients studied 
ranged from 10.7- 117 cc (cm3), with mean and standard deviation (STD) of 45 cc and 28 cc 
respectively (Figure 2). The number of beams used for the various treatment plans ranged 
from 8 to 12.  The number of beams used for each case is labeled in the same figure. One can 
observe from the figure that there was no correlation between the PTV volume and number of 
beams necessary to adequately treat the volume. The photon beam energy used was 6 MV. 
Figure 3 shows the isodose distributions without (left) and with (right) heterogeneity correction 
on the isocentric axial slice for one of the cases submitted. It can be observed that with 
heterogeneity correction applied, the prescription isodose line contracts while the 50% isodose 
line extends, which is reflected in the dose volume histogram for the PTV (Figure 4). The 
percent volume receiving 60 Gy decreases from 95% to 60% in this case. 
The statistical changes of the plans with vs. without heterogeneity corrections are described in 
the following categories: isocenter dose, 95% of PTV volume dose coverage, 99% of PTV 
volume dose coverage, conformality of PTV coverage, and dose to critical structures. 
Isocenter dose: 
Figure 5 shows the effect on the isocenter dose as heterogeneity corrections are applied using 
the non-corrected monitor units.  Of the submitted plans with unit density applied, the 
isocentric dose ranges from 66.3 Gy to 82.2 Gy (mean 70.1 Gy, standard error (SE) 0.9 Gy). 
With heterogeneity corrections applied, the isocenter dose ranges from 71.3 Gy to 88.9 Gy 
(mean 78.8 Gy, SE 1.1 Gy). Included in Figure 5 are also the ratios of isocentric dose with 
heterogeneity corrections over those without. One observes that all the ratios are greater than 
or equal to one, meaning an increase of isocentric doses for all these submitted cases. The 
relative increases range between -0.1% and 22% (mean 12.5%, and SE 1.2%).  
95% of PTV volume dose coverage: 
The protocol requires that 95% of the target volume (PTV) be conformally covered by the 
prescription isodose surface of 60 Gy with no heterogeneity correction applied.  As shown in 
Figure 6, the actual percentage of the PTV receiving the prescription dose of 60 Gy (%V60) 
ranges from 89.6% - 98.8% (mean 95.8%, SE 0.5%).  Deviations from the required 95% have 
a minimum of -5.4% to a maximum of 3.8% (mean 0.8%, SE 0.5%). With heterogeneity 
corrections applied (Figure 6), V60 deviation from 95% has a wider range, from -37.4% to 2.7% 
(mean -10.1%, SE 2.7%). The mean difference ranges from -37.4% to 1.2% (mean -10.8%, SE 
2.8%, p=0.001). 
Considering the dose delivered to 95% of the PTV (D95) for the unit density calculations, values 
ranged from 57.0 Gy to 63.5 Gy (mean 60.6 Gy, SE 0.3 Gy). With heterogeneity correction 
applied, D95 extends to a wider range from 44.1 Gy to 64.2 Gy (mean 55.9, SE 1.1 Gy). The 
per-patient difference ranges from -16.0 Gy to 0.7 Gy (mean -4.7 Gy, SE 1.0 Gy, p=0.0002). 
99% of PTV volume dose coverage: 
The protocol requires that the percent volume receiving 90% of the prescription dose (54 Gy) 
be no less than 99%.   This requirement is met by almost all the plans (Figure 7), with a 
minimum of 97.7% and a maximum 100% (mean 99.2%, SE 0.1%). For the heterogeneity 
corrected plans, the deviation from 99% can be as much as -20.5%, with 4 cases deviating 
more than 5% (Figure 7).  The per-patient differences range from -20.% to 0.5% (mean -4.1%, 
SE 1.3%, p=0.006).  Similar results are seen in the dose to 99% of the volume (D99).  This 
parameter extends from a minimum of 49.8 Gy to a maximum 59.6 Gy  (mean 55.1 Gy, SE 0.5 
Gy) when unit density calculations are performed, and to a range of 38.4 Gy to 73 Gy (51.4 Gy, 
SE 1.6 Gy) with heterogeneity correction. The per-patient difference ranges from -16.1 Gy to 
14.2 Gy (mean -3.7 Gy, SE 1.4 Gy, p=0.02). The D90 for non-corrected planning has a range of  
59.8 Gy to 67.7 Gy (mean 62.7 Gy, SE 0.3 Gy), and heterogeneity corrected plans range from 
47.9 Gy to 68.6 Gy (mean 58.9 Gy, SE 1.1 Gy). The per-patient difference ranges from -14.2 
Gy to 1.8 Gy (mean -3.8 Gy, SE 1.0 Gy, p=0.001). 
Conformality of PTV coverage: 
The RTOG 0236 protocol forces conformality of PTV coverage by limiting the ratio of the 
volume of the prescription isodose to the volume of the PTV.  The requirement is that this ratio 
must be equal to or less than 1.4 when the dose calculation assumes unit density for all 
tissues (see Table 1). Under these conditions, the calculated ratio for the 20 cases has a 
minimum value of 0.9 and maximum value of 1.7 (mean 1.2, SE 0.045), with only 2 cases 
violating the limit of 1.4.  With the heterogeneity correction applied, the isodose volume for the 
prescription dose decreased. In this case the minimum ratio was 0.6 and the maximum ratio 
was 1.5 (mean 1.0, SE 0.045).  Only 1 case violates the upper limit of 1.4. 
Maximum dose to any point 2 cm or greater away from the PTV in any direction (D2cm) varied 
between 20.7 Gy as a minimum value to 49.1 Gy as a maximum (mean 35.2 Gy, SE 1.7 Gy) 
for unit density calculation.  This parameter ranged from 20.3 Gy to 56.0 Gy (mean 38.5, SE 
2.2 Gy) with heterogeneity corrections.  The per-patient difference ranged from -1.1 Gy to 8.2 
Gy (mean 3.3 Gy, SE 0.6 Gy, p<0.0001). These numbers indicate, unlike the isodose line for 
the prescription dose, the shift of the lower value isodose lines is away from the isocenter as 
shown in Figure 3.  Since future SBRT lung protocols will be designed to use heterogeneity 
corrected treatment planning, it is important to modify the dose constraints stated in the RTOG 
0236 protocol to better reflect the actual delivered doses. This modification is included in Table 
1 under the heading “Hetero.”  Notice that the ratio of the 60 Gy isodose volume to the total 
PTV volume has not been changed.  The maximum dose at 2 cm distance from the PTV has 
been modified.  The numbers given in the table are the values that trigger a major deviation for 
the submitted case.  The comparison between non-corrected and heterogeneity corrected 
maximum doses at 2 cm from the PTV is shown in the table.  It can be seen that the D2cm 
values as stated in the 0236 protocol for the unit density treatment plans are consistently lower 
than the D2cm values for the heterogeneity corrected plans.   
Another measure of the dose distribution comformality used in the RTOG 0236 protocol is the 
volume of the isodose surface for the dose that is 50% of the prescription dose value.  For the 
50% isodose spillage, the protocol requires that the ratio of the volume within an isodose 
surface for 50% of the prescription dose (30 Gy for homogeneous calculation and 56 Gy for 
heterogeneity corrected calculations) to the volume of the PTV (R50%) must be no greater than 
the R50% value specified in Table 1.  The R50% values in this table were determined based on 
unit density dose calculation and are dependent upon PTV volume. It is interesting to compare 
the R50% values for the plans based on unit density calculations to the plans with heterogeneity 
correction applied.  The R50% value for the unit density plans have a minimum value of 2.9, and 
a maximum of 6.3 (mean 3.8, SE 0.2) as compared to a minimum of 3.2 and a maximum of 6.5 
(mean 4.3, SE 0.2) for the plans with heterogeneity corrections. The ratio between the 
R50%value over its corresponding criterion increases from 1.0 ± 0.2 (minimum 0.7, maximum 
1.5) to 1.1 ± 0.2 (minimum 0.8, maximum 1.6). The percent pass rate (ratio <=1.0) decreases 
from 70% to 35%. 
Critical structures: 
For the critical structures, the percent lung volume receiving 20 Gy or more (V20) is limited to 
be not more than 10% per the protocol, with no deviation defined as < 10% and a minor 
deviation defined at 10-15%(Table 1). Due to the relatively small size and location of the target 
volumes from the submitted cases, this criterion is met by almost all cases with a large margin 
(mean 5.5%, SE 0.6%, range = 2.5% – 12.7%). With changes from the heterogeneity 
correction, percent lung volume receiving 20 Gy is still well under the required upper limit of 
10% (mean 5.9%, SE 0.6%, range = 2.5% – 14.1%). One case that doesn’t meet the criterion 
before correction (12.7%) still deviates from the limit after correction (14.1%).  The per-patient 
difference with heterogeneity corrections ranges from -0.1% - 1.4% (mean 0.3%, SE 0.1%, p = 
0.0003). 
The absolute maximum dose limits for other critical structures are listed in Table 2. Without 
heterogeneity corrections, the dose to the spinal cord ranges from 0.4 Gy to 18.5 Gy (mean 
9.9 Gy, SE 1.3 Gy).  With heterogeneity correction, the range is 0.3 Gy to 22.0 Gy (mean 10.9 
Gy, SE 1.4 Gy).  The per-patient difference ranges from -0.3 Gy to 3.7 Gy (mean 0.9 Gy, SE 
0.3 Gy, p = 0.006). One case with maximum dose to the spinal cord greater than the 18 Gy 
limit (18.5 Gy) before correction increases its value to 22 Gy after correction. Due to the fact 
that the submitted cases all have target volumes distal from the mediastinum, the doses to 
esophagus, heart and the other critical structures listed in Table 2 are negligible. However, one 
out of twenty cases has esophagus receiving a maximum dose of 6.1 Gy without heterogeneity 
correction, which increases to 12.0 Gy with the correction. Two out of the twenty cases having 
esophagus maximum doses of 0.0 Gy without correction see an increase of maximum 
esophagus doses to 0.3 Gy and 11.9 Gy respectively after the correction, showing potentially 
substantial dose increase to nearby critical structures with heterogeneity correction.  
Suggested prescribed dose and constraint adjustments for protocols with 
heterogeneity correction: 
Based on the results presented above for 20 cases submitted for the RTOG 0236 protocol, 
there is a need to adjust prescribed dose and constraints that control conformality for future 
protocols that use heterogeneity corrections. It is recommended here that future protocols that 
are patterned after the RTOG 0236 protocol in terms of total prescribed dose and dose 
fractionation use a prescribed dose of 56 Gy instead of the 60 Gy used for homogeneous 
tissue density calculations.  Suggested values for adjusted constraints are listed in Table 1 
under the column “hetero”. These values are obtained so that approximately 80% of the 
submitted cases meet the criteria with heterogeneity correction, since re-optimization of beam 
weights are not performed for these heterogeneity corrected plans. 
Because of the characteristics of the target volumes, which are distal from the mediastinum for 
the submitted cases, the percentage of cases meeting the criteria to cord, esophagus, heart 
and the other critical structures listed in Table 2 is not affected by turning on the heterogeneity 
correction. No changes are recommended for the values in Table 2 with heterogeneity 
correction for similar cases. 
Conclusions:  
Significant differences are found between the calculated doses submitted to meet the 
requirements of RTOG 0236 and the actual heterogeneity corrected doses.  These results are 
similar to the single-institutional findings of reference 20.  The volume of PTV receiving 
prescription dose decreases over 10% on average. Dose to 95% of the PTV volume 
decreased on average by 4.7 Gy.  Dose spilling to normal tissues noticeably increased in only 
a limited number of patients with heterogeneity corrections applied.  However, in a few of these 
cases, the increases were marked and exceeded the protocol specified constraints. The 
design of the RTOG 0236 protocol was patterned on pilot studies that did not use tissue 
heterogeneity corrections for the treatment planning.  The information provided in the current 
study will be used for designing future RTOG protocols to better match the true dose delivered 
for RTOG 0236.  Adjusting the dose for future studies is extremely important given the 
hypofractionated dose schedule and reduced margins used for RTOG 0236. 
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 Table 1. Dosimetric criteria for target coverage, “Homo” are for unit density and “Hetero” are 
suggested adjustments to be used when heterogeneity correction are applied. 
 
Ratio of 
Prescription 
Isodose 
Volume 
 to the PTV 
Ratio of 50% 
Prescription 
 Isodose 
Volume 
to the PTV, 
R50%  
  
Maximum Dose 
2 cm from PTV 
in any Direction, 
D2cm  
% of Prescription 
Dose 
Percent of Lung 
receiving 20 Gy 
total or more, 
V20 (%) 
Major 
Deviation 
Major 
Deviation 
Major 
Deviation 
Maximum 
PTV 
Dimension 
(cm) 
  
  
  
Homo 
60 Gy 
Hetero 
56 Gy 
Homo Hetero Homo Hetero 
Major 
Deviation 
PTV 
Volume 
(cc) 
  
  
  
  
2 >1.4 >4.1 >7.0 >50.2 >55.2 >15 1.8 
2.5 >1.4 >4.1 >5.8 >50.2 >55.2 >15 3.8 
3 >1.4 >4.1 >5.4 >50.2 >55.2 >15 7.4 
3.5 >1.4 >4.1 >5.3 >50.2 >55.2 >15 13.2 
4 >1.4 >4.0 >5.2 >54.0 >59.7 >15 21.9 
4.5 >1.4 >3.9 >5.0 >57.8 >62.8 >15 33.8 
5 >1.4 >3.8 >4.8 >61.8 >75.2 >15 49.6 
5.5 >1.4 >3.7 >4.5 >69.5 >83.8 >15 69.9 
6 >1.4 >3.5 >4.1 >69.5 >86.8 >15 95.1 
6.5 >1.4 >3.3 >3.7 >73.3 >88.7 >15 125.8 
7 >1.4 >3.1 >3.5 >77.2 >90.7 >15 162.6 
Table 2. Dose limits for critical structures 
 
 
Organ  Volume  Dose (cGy) 
Spinal Cord  Any point   18 Gy   
Esophagus  Any point   27 Gy   
Ipsilateral Brachial Plexus  Any point   24 Gy  
Heart  Any point   30 Gy   
Trachea and Ipsilateral Bronchus  Any point   30 Gy   
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 Figure 1 The non-coplanar beam arrangement for the 3D conformal planning of the 
stereotactic radiation treatment (PTV and cord are shown in solid, orientation icon labels: 
H:head, R:Right, L:Left). 
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Figure 2 - PTV volume distribution and the number of beams (given above each bar) employed 
for the radiotherapy treatment plan. 
 Figure 3 Isodose distributions for with unit density (left) and with density corrections (right). The 
dashed lines are PTV (inside) and 2 cm from PTV (outside). The solid lines are for 60 Gy 
isodose (inside) and 30 Gy isodose (outside). 
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Figure 4 Dose volume histograms for PTV coverage with unit density and with density 
correction, for the case shown in Figure 3, one of the cases with larger than average 
differences between heterogeneity corrected and unit density plans chosen for illustration. 
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Figure 5 Doses at isocenter point for all the plans with and without heterogeneity correction. 
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Figure 6 Percent volume that receives prescription dose 60 Gy or higher, as compared against 
the protocol required value of 95%, without and with heterogeneity correction. 
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Figure 7 Percent volume that receives 90% of prescription dose: 54 Gy or higher, as compared 
against the protocol required value of 99%, without and with heterogeneity correction. 
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